Koers WuXi Biologics (Cayman) Inc. Hong Kong S.E.
Aandelen
2269
KYG970081090
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 18,16 mld. 2,51 mld. 19,62 mld. 2,31 mld. | Omzet 2025 * | 21,73 mld. 3,01 mld. 23,47 mld. 2,77 mld. | Marktkapitalisatie | 54,12 mld. 7,49 mld. 58,46 mld. 6,89 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 3,88 mld. 537 mln. 4,19 mld. 494 mln. | Nettowinst (verlies) 2025 * | 4,92 mld. 681 mln. 5,31 mld. 626 mln. | EV/omzet 2024 * | 2,6 x |
Nettoliquiditeiten 2024 * | 6,92 mld. 958 mln. 7,48 mld. 882 mln. | Nettoliquiditeiten 2025 * | 7,83 mld. 1,08 mld. 8,46 mld. 997 mln. | EV/omzet 2025 * | 2,13 x |
K/w-verhouding 2024 * |
14,4
x | K/w-verhouding 2025 * |
11,3
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 85,47% |
Recentste transcriptie over WuXi Biologics (Cayman) Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 52 | 01-06-11 |
Ming Tu
DFI | Director of Finance/CFO | 54 | 23-08-21 |
Gu Jijie
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jackson Tai
BRD | Director/Board Member | 73 | 06-05-23 |
William Keller
BRD | Director/Board Member | 75 | 17-05-17 |
Ge Li
CHM | Chairman | 56 | 01-05-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 115 mld. | |
+11,84% | 106 mld. | |
-1,05% | 21,96 mld. | |
-14,15% | 21,84 mld. | |
-5,29% | 19,21 mld. | |
-4,16% | 18,08 mld. | |
-38,29% | 17,71 mld. | |
+7,99% | 14,32 mld. | |
+36,24% | 12,42 mld. |